Recently, studies have investigated the role of sodium glucose transporter 2 (SGLT2) inhibitors, such as empagliflozin, on modulating cardiac alterations in obesity-related T2DM. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.